Rotigotine API is a synthetic non-ergoline dopamine receptor agonist used as an active pharmaceutical ingredient in transdermal formulations. It is particularly associated with the treatment of Parkinson's disease and restless legs syndrome. Rotigotine provides continuous dopaminergic stimulation through transdermal delivery.
Rotigotine is the S-enantiomer of the active compound and contains one defined stereocenter. The USP-NF monograph identifies Rotigotine with the molecular formula C19H25NOS and molecular weight 315.48 g/mol.
Rotigotine is chemically identified as (6S)-6-[propyl[2-(2-thienyl)ethyl]amino]-5,6,7,8-tetrahydro-1-naphthalenol. It contains a tetrahydronaphthol structure linked to a substituted amino group and a thiophene-containing side chain.
FDA identifies Rotigotine as a chemical substance with absolute stereochemistry, one defined stereocenter and negative optical activity.
Rotigotine API is primarily used in transdermal pharmaceutical products for continuous delivery over 24 hours.
Its established pharmaceutical applications include:
The marketed transdermal system provides continuous delivery of Rotigotine for 24 hours.
Rotigotine is a non-ergoline dopamine agonist. It stimulates dopamine receptors in the central nervous system and provides dopaminergic activity relevant to the motor symptoms associated with Parkinson's disease.
Its transdermal delivery system is designed to provide continuous exposure to the active ingredient over a 24-hour period.
Rotigotine API is subject to established compendial quality requirements. The current USP-NF monograph defines Rotigotine as containing 98.0%–102.0% of Rotigotine on the applicable basis. Identification includes infrared spectroscopy and chromatographic confirmation of the Rotigotine S-isomer.
Quality evaluation includes appropriate controls for:
The USP monograph specifically includes testing for the Rotigotine R-enantiomer and organic impurities, making stereochemical purity an important quality attribute of the API.
Rotigotine API is manufactured through controlled chemical synthesis followed by purification and isolation of the required S-enantiomer.
Because Rotigotine is a stereochemically defined API, manufacturing and purification controls are important for maintaining the required S-isomer and limiting the corresponding R-enantiomer and other process-related impurities.
The final API is subjected to validated analytical testing to confirm identity, assay, stereochemical purity and chemical purity.
Rotigotine is a white to off-white powder according to the FDA clinical pharmacology review.
Key characteristics include:
Rotigotine API should be packed in suitable pharmaceutical-grade containers that protect the material from contamination, moisture and unsuitable environmental exposure.
Storage conditions should follow the approved API specification and validated stability data. Containers should remain appropriately closed during storage and handling.
A qualified Rotigotine API manufacturer can provide applicable quality and regulatory documentation, including:
A qualified Rotigotine API manufacturer in India can support pharmaceutical companies requiring consistent-quality Rotigotine for transdermal pharmaceutical development and manufacturing.
Important quality considerations include the correct S-stereochemical form, assay, R-enantiomer control, organic impurity control and consistent physical characteristics.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Residue on Ignition | NMT 0.1% |